TGFB1 and cancer: Similar to UNC0642 and A366, BRD4770 treatment of cancer cells enhanced their NK cell-mediated cytotoxicity (Fig. EV8A), stimulated the expression of AZGP1 (Fig. EV8B,C), and suppressed the expression of TGF-β1 (Fig. EV8D,E).